CLINICAL TRIALS PAST 5 YEARS

Building Bridges

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

Year completed

Indication

Phase

R*

Specification

No. of centres**

No. of patients**

Countries involved***

 

 

 

 

 

 

 

 

               
scheduled Pre-menstrual Syndrome

III

  Phyto- pharm. IMP 10 130 CR

ongoing

Vulvo-vaginal Candidiasis

III

 

Medical device

02

50

CR

2014

Influenza

III

 

Phyto vs Tamiflu

30

500

CR

2013

Cardiology (BE long-term)

I

R3

Coop. with P1-partner

01

24

CR

2012

Ulcerative colitis

--

 

Medical Device

02

12

CR

2012

Cardiology (BE short term)

I

R3

Coop. with P1-partner

01

24

CR

2012

Renal impairment

II

 

Pharmaco-kinetics

02

25

CR

2012

Mastalgia/ PMS

III

R4

Phyto-pharm. IMP

11

190

CR

2011

Acromegaly/Macroadenoma

III

R2

Macroadenoma

03

20

CR, (EU)

2011

Colitis ulcerosa

--

 

Medical device

02

12

CR (EU)

2011

Cardiology (BE study)

I

3

Coop. with P1-partner

01

16

CR

2010

In-vitro Fertilisation

II

R1

Uterine contractions

02

30

CR, (EU)

2010

Anemia

III

 

Pre-dialysis patients

15

80

CR, SK (EU)

2009

Acromegaly

III

2

 

02

20

CR, (EU)

2009

Renal Cell Carcinoma

II

 

Vaccination

04

ET

CR, A

2009

Premature ejaculation

III

 

 

05

30

CR, PL

2008

In-vitro Fertilisation

IIa

R1

Donor stimulation

01

20

CR (EU)

2008

In-vitro Fertilisation

II

1

Uterine contractions

02

35

CR, (EU)

2008

Diabetes mellitus type II

II

 

First long-term appl.

05

20

CR (EU)

2008

Mild Cognitive Impairment

III

 

Phyto- pharm. IMP

25

ET

CR, SK

 

*

Repeat business (consecutive trial(s) by the same sponsor)

**

No. of patients enrolled, share in CEE- countries managed by PHAMOS (ET= early terminated due to sponsor’s strategic decision)

***

Countries managed by PHAMOS, in brackets other countries not managed by PHAMOS but by sponsor or other CROs (EU stands for more than one other EU country)

Other trials performed on:

Dysrhythmia, Heart failure, MI acute (fibrinolysis), Small gestation age, Hormonal Replacement Therapy, Osteoporosis treat­ment, Post-menopausal syndrome, Pre-menstrual syndrome, Anaemia, Hypertension, Dementia, Depression, Multiple Scle­rosis , Conjuctivitis, Anti-infective therapy and prophylaxis, Bronchitis, COPD, Osteoarthritis, Prostate cancer, Urinary incon­tinence (adults and children)

Sponsors we have been working for:

AOP Orphan, Apogepha, Asahi KKM, Bionorica, Bioforce, Boehringer Ingelheim, Daiichi-Sankyo, Dentinox, Falk Pharma, Ferring, Hexal Bio­tech, Ipsen, Jena­pharm, Lilly, Madaus, Medinova, Merckle, Novartis, NovoNordisk, Parke Davis, Plantamed, Plethora Solutions, Sandoz, Schering, Schwabe, Serono, S&K Pharma, Slovakopharma, SKB, Takeda, Trimed Biotech, USV India, Wyeth, Yamanouchi